Biologists are faced with a range of options to publish in journals that vary dramatically in scope and selectivity.
Biologists are faced with a range of options to publish in journals that vary dramatically in scope and selectivity. Scientific societies such as the American Society for Cell Biology, the American Society for Life science scholars often rely on the perceived importance of a publication venue as reflected in the numeric "impact factor". This flawed measure gives undue influence to a minority of papers that generate large numbers of citations that boost the appearance of impact for papers that may generate few citations. Many scientific societies and life science scholars have urged that the use of impact factor be reduced or eliminated in considering the scholarly contributions of junior and senior colleagues (http://am.ascb.org/dora/)
In an effort to create a new venue for the most important contributions in the life sciences, the Howard Hughes Medical Institute, the Wellcome Trust and the Max Planck Society have joined forces to create a new journal, eLife. The premise of eLife is to return the decision making process to active scientists in an Open Access forum where work is judged in a consultative manner and the author is given clear decision without the need for many rounds of time consuming and expensive revisions. At eLife, all editorial decisions are made by an internationally distinguished group of scientific editors. With generous support from the founding agencies, authors are able to publish work with no page charges for the next several years. Read about the journal and sign up for eLife alerts (http://www.elifesciences.org).
